Clinical Research
Please contact your provider to learn if you are eligible for any of our enrolling clinical trials.
What Participants Can Expect
Participants in our clinical trials may:
- Gain a deeper understanding of their eye condition
- Access investigational treatments that are not yet widely available
- Receive study-related eye exams at no cost (insurance is not required)
- Be closely monitored by our experienced medical and research staff
- Potentially be eligible for a modest stipend to help offset time and travel associated with participation
By participating in a clinical trial, you contribute to the development of future treatments that may benefit others living with similar conditions.
Geographic Atrophy
Astellas Reveal 3021-MA-3543
Offices: Toms River, Edison, & Teaneck
A Non-Interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY™) in Routine Clinical Practice in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
Regeneron Sienna R3918-AMD-2326
Offices: Toms River & Teaneck
A multicenter, randomized, double-masked, placebo-controlled phase 3 study of the efficacy, safety, and tolerability of subcutaneously administered pozelimab in combination with cemdisiran or cemdisiran alone in participants with geographic atrophy secondary to age-related macular degeneration.
Apellis Gallop APL3007-GA-201
Offices: Edison & Toms River
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneration
Bionic Sight BS01-GA-001
Offices: Edison
A Phase 1/2 Study to Evaluate the Safety and Efficacy of Intravitreal Administration of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP (AAV2-CAGChronosFP) in Patients With Geographic Atrophy Secondary to Dry AMD
Novartis CIRCLE CFWY003A12201
Offices: Edison
A Randomized, Double Masked, Placebo-controlled, Multicenter, Dose-range Finding Study to Assess the Efficacy and Safety of FWY003 in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration
Retinitis Pigmentosa
jCyte – JC02-88
Offices: Teaneck
A Randomized, Masked, Sham-Controlled Phase 2 Trial of the Safety of a Single Intravitreal Injection of jCell (Famzeretcel) for the Treatment of Retinitis Pigmentosa (RP)
Diabetic Macular Edema
Eyepoint COMO EYE-1901-303
Offices: Toms River & Teaneck
A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept (2 mg) in Participants With Diabetic Macular Edema (DME)